Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence

被引：77

作者：

Cosman, F ^{[1
]}

Lindsay, R

机构：

[1] Helen Hayes Hosp, Reg Bone Ctr, Clin Res Ctr, W Haverstraw, NY 10993 USA

[2] Columbia Presbyterian Med Ctr, Dept Med, New York, NY 10032 USA

来源：

CALCIFIED TISSUE INTERNATIONAL | 1998年 / 62卷 / 06期

关键词：

hormone replacement therapy; estrogen; salmon calcitonin; alendronate; bone turnover;

D O I：

10.1007/s002239900464

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Most of the data on the anabolic effect of PTH have been obtained with hPTH(1-34). Studies have shown a marked increment in spinal bone mass. Most recently we have shown that PTH and estrogen can be given together where there is increased total bone mineral and no loss of bone at any skeletal site. We have also shown the first reduction in vertebral deformity incidence due to PTH treatment.

引用

页码：475 / 480

页数：6

共 90 条

[1] Azria Moise, 1996, P1083
[2] BIOCHEMICAL EFFECTS OF 17-BETA-ESTRADIOL ON UMR106 CELLS
BANKSON, DD
RIFAI, N
WILLIAMS, ME
SILVERMAN, LM
GRAY, TK
[J]. BONE AND MINERAL, 1989, 6 (01): : 55 - 63
[3] Studies of calcium and phosphorus metabolism. V. A study of the bone trabeculae as a readily available reserve supply of calcium.
Bauer, W
Aub, JC
Albright, F
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1929, 49 (01) : 145 - U19
[4] RESPONSE OF CORTICAL BONE TO ANTIRESORPTIVE AGENTS AND PARATHYROID-HORMONE IN AGED OVARIECTOMIZED RATS
BAUMANN, BD
WRONSKI, TJ
[J]. BONE, 1995, 16 (02) : 247 - 253
[5] Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Black, DM
Cummings, SR
Karpf, DB
Cauley, JA
Thompson, DE
Nevitt, MC
Bauer, DC
Genant, HK
Haskell, WL
Marcus, R
Ott, SM
Torner, JC
Quandt, SA
Reiss, TF
Ensrud, KE
[J]. LANCET, 1996, 348 (9041) : 1535 - 1541
[6] TREATMENT OF OSTEOPOROSIS WITH PARATHYROID PEPTIDE (HPTH 1-34) AND ESTROGEN - INCREASE IN VOLUMETRIC DENSITY OF ILIAC CANCELLOUS BONE MAY DEPEND ON REDUCED TRABECULAR SPACING AS WELL AS INCREASED THICKNESS OF PACKETS OF NEWLY FORMED BONE
BRADBEER, JN
ARLOT, ME
MEUNIER, PJ
REEVE, J
[J]. CLINICAL ENDOCRINOLOGY, 1992, 37 (03) : 282 - 289
[7] ESTROGEN DOSE REQUIRED TO MAINTAIN PARATHYROID-HORMONE MEDIATED BONE GAIN IN OSTEOPENIC OVARIECTOMIZED RATS IS PROBABLY HIGHER THAN IN PREVENTIVE TREATMENT WITH ESTROGEN
CHENG, PT
AYE, LM
VIETH, R
MULLER, K
[J]. BONE, 1995, 17 (04) : S329 - S334
[8] ESTROGEN PROTECTION AGAINST BONE RESORBING EFFECTS OF PARATHYROID-HORMONE INFUSION - ASSESSMENT BY USE OF BIOCHEMICAL MARKERS
COSMAN, F
SHEN, V
XIE, F
SEIBEL, M
RATCLIFFE, A
LINDSAY, R
[J]. ANNALS OF INTERNAL MEDICINE, 1993, 118 (05) : 337 - 343
[9] COSMAN F, IN PRESS J BONE MINE
[10] THE ANABOLIC EFFECT OF HUMAN PTH(1-34) ON BONE-FORMATION IS BLUNTED WHEN BONE-RESORPTION IS INHIBITED BY THE BISPHOSPHONATE TILUDRONATE - IS ACTIVATED RESORPTION A PREREQUISITE FOR THE IN-VIVO EFFECT OF PTH ON FORMATION IN A REMODELING SYSTEM
DELMAS, PD
VERGNAUD, P
ARLOT, ME
PASTOUREAU, P
MEUNIER, PJ
NILSSEN, MHL
[J]. BONE, 1995, 16 (06) : 603 - 610

← 1 2 3 4 5 6 7 8 9 →